$SSY
SUNLINK HEALTH SYSTEMS INC

2024 Q2 Form 10-Q Financial Statement

#000095017024060341 Filed on May 15, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $7.913M $7.462M
YoY Change -27.98% -35.3%
Cost Of Revenue $4.382M $4.339M
YoY Change -11.1% -8.75%
Gross Profit $3.531M $3.123M
YoY Change -41.71% -53.92%
Gross Profit Margin 44.62% 41.85%
Selling, General & Admin $3.058M $3.045M
YoY Change -50.61% -48.97%
% of Gross Profit 86.6% 97.5%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $413.0K $342.0K
YoY Change -30.7% -17.39%
% of Gross Profit 11.7% 10.95%
Operating Expenses $4.206M $3.976M
YoY Change -47.64% -47.35%
Operating Profit -$675.0K -$853.0K
YoY Change -65.82% 10.21%
Interest Expense $23.00K $19.00K
YoY Change -68.92% -53.66%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$652.0K -$834.0K
YoY Change -54.6% 13.78%
Income Tax $0.00 -$10.00K
% Of Pretax Income
Net Earnings $4.288M -$1.396M
YoY Change -400.7% 83.2%
Net Earnings / Revenue 54.19% -18.71%
Basic Earnings Per Share -$0.20
Diluted Earnings Per Share $0.60 -$0.20
COMMON SHARES
Basic Shares Outstanding 7.041M 7.041M
Diluted Shares Outstanding 7.041K

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.170M $1.211M
YoY Change 59.83% -77.5%
Cash & Equivalents $7.170M $1.211M
Short-Term Investments
Other Short-Term Assets $3.570M $5.116M
YoY Change 100.22% 193.85%
Inventory $1.553M $1.561M
Prepaid Expenses
Receivables $3.371M $3.078M
Other Receivables $0.00 $0.00
Total Short-Term Assets $15.66M $10.97M
YoY Change 27.62% -17.57%
LONG-TERM ASSETS
Property, Plant & Equipment $2.809M $2.903M
YoY Change -66.08% -65.42%
Goodwill
YoY Change
Intangibles $1.180M $1.180M
YoY Change 0.0% -0.17%
Long-Term Investments
YoY Change
Other Assets $443.0K $503.0K
YoY Change -9.41% -16.58%
Total Long-Term Assets $4.948M $5.178M
YoY Change -55.0% -53.46%
TOTAL ASSETS
Total Short-Term Assets $15.66M $10.97M
Total Long-Term Assets $4.948M $5.178M
Total Assets $20.61M $16.14M
YoY Change -11.42% -33.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.905M $1.532M
YoY Change 3.03% -2.36%
Accrued Expenses $2.308M $1.864M
YoY Change -22.71% -28.72%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change -100.0%
Total Short-Term Liabilities $4.213M $3.959M
YoY Change -13.47% -15.35%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $180.0K $73.00K
YoY Change 76.47% -62.94%
Total Long-Term Liabilities $426.0K $577.0K
YoY Change -56.66% -39.52%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.213M $3.959M
Total Long-Term Liabilities $426.0K $577.0K
Total Liabilities $4.639M $4.536M
YoY Change -20.73% -19.45%
SHAREHOLDERS EQUITY
Retained Earnings $1.478M -$2.810M
YoY Change -50.82% -163.42%
Common Stock $14.27M $14.27M
YoY Change 0.04% 0.04%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $15.97M $11.61M
YoY Change
Total Liabilities & Shareholders Equity $20.61M $16.14M
YoY Change -11.42% -33.92%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income $4.288M -$1.396M
YoY Change -400.7% 83.2%
Depreciation, Depletion And Amortization $413.0K $342.0K
YoY Change -30.7% -17.39%
Cash From Operating Activities -$386.0K -$1.062M
YoY Change -8.31% -275.25%
INVESTING ACTIVITIES
Capital Expenditures $385.0K $282.0K
YoY Change -18.95% -24.6%
Acquisitions
YoY Change
Other Investing Activities $6.730M $500.0K
YoY Change 61081.82%
Cash From Investing Activities $6.345M $218.0K
YoY Change -1467.46% -158.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000
YoY Change -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -386.0K -1.062M
Cash From Investing Activities 6.345M 218.0K
Cash From Financing Activities 0.000 0.000
Net Change In Cash 5.959M -844.0K
YoY Change -765.07% -473.45%
FREE CASH FLOW
Cash From Operating Activities -$386.0K -$1.062M
Capital Expenditures $385.0K $282.0K
Free Cash Flow -$771.0K -$1.344M
YoY Change -13.95% -679.31%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0000096793
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 us-gaap Common Stock No Par Value
CommonStockNoParValue
CY2023Q2 us-gaap Common Stock No Par Value
CommonStockNoParValue
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
1-12607
dei Entity Registrant Name
EntityRegistrantName
SUNLINK HEALTH SYSTEMS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
GA
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
31-0621189
dei Entity Address Address Line1
EntityAddressAddressLine1
900 Circle 75 Parkway
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 690
dei Entity Address City Or Town
EntityAddressCityOrTown
Atlanta
dei Entity Address State Or Province
EntityAddressStateOrProvince
GA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
30339
dei City Area Code
CityAreaCode
770
dei Local Phone Number
LocalPhoneNumber
933-7000
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7040603
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1211000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4486000
CY2024Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
3078000
CY2023Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
2592000
CY2024Q1 us-gaap Inventory Net
InventoryNet
1561000
CY2023Q2 us-gaap Inventory Net
InventoryNet
1628000
CY2024Q1 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
3512000
CY2023Q2 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
1920000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1604000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1648000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
10966000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
12274000
CY2024Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12302000
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11259000
CY2024Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9399000
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8542000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2903000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2717000
CY2024Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1180000
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1180000
CY2024Q1 ssy Assetsheldforsalenotpartofdisposalgroupnoncurrent
Assetsheldforsalenotpartofdisposalgroupnoncurrent
0
CY2023Q2 ssy Assetsheldforsalenotpartofdisposalgroupnoncurrent
Assetsheldforsalenotpartofdisposalgroupnoncurrent
5812000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
592000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
798000
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
503000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
487000
CY2024Q1 us-gaap Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment
AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment
2275000
CY2023Q2 us-gaap Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment
AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment
8277000
CY2024Q1 us-gaap Assets
Assets
16144000
CY2023Q2 us-gaap Assets
Assets
23268000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1532000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1067000
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
857000
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1027000
CY2024Q1 ssy Current Liabilities Held For Sale
CurrentLiabilitiesHeldForSale
563000
CY2023Q2 ssy Current Liabilities Held For Sale
CurrentLiabilitiesHeldForSale
1326000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
332000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
334000
CY2024Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
675000
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1115000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
3959000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4869000
CY2024Q1 ssy Professional Liability Risks Non Current
ProfessionalLiabilityRisksNonCurrent
231000
CY2023Q2 ssy Professional Liability Risks Non Current
ProfessionalLiabilityRisksNonCurrent
138000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
273000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
481000
CY2024Q1 ssy Noncurrent Liabilities Held For Sale
NoncurrentLiabilitiesHeldForSale
0
CY2023Q2 ssy Noncurrent Liabilities Held For Sale
NoncurrentLiabilitiesHeldForSale
192000
CY2024Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
73000
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
171000
CY2024Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
577000
CY2023Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
982000
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2024Q1 us-gaap Preferred Stock Share Subscriptions
PreferredStockShareSubscriptions
2000000
CY2023Q2 us-gaap Preferred Stock Share Subscriptions
PreferredStockShareSubscriptions
2000000
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7041000
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7041000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7032000
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7032000
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
3521000
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
3516000
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
10747000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
10746000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2810000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
3005000
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
150000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
150000
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
11608000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
17417000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16144000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
23268000
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7462000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8181000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
24527000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
26270000
CY2024Q1 us-gaap Labor And Related Expense
LaborAndRelatedExpense
2652000
CY2023Q1 us-gaap Labor And Related Expense
LaborAndRelatedExpense
2543000
us-gaap Labor And Related Expense
LaborAndRelatedExpense
7937000
us-gaap Labor And Related Expense
LaborAndRelatedExpense
7547000
CY2024Q1 us-gaap Supplies Expense
SuppliesExpense
36000
CY2023Q1 us-gaap Supplies Expense
SuppliesExpense
39000
us-gaap Supplies Expense
SuppliesExpense
109000
us-gaap Supplies Expense
SuppliesExpense
104000
CY2024Q1 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
589000
CY2023Q1 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
601000
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
2279000
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
1854000
CY2024Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
92000
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
92000
us-gaap Operating Lease Expense
OperatingLeaseExpense
275000
us-gaap Operating Lease Expense
OperatingLeaseExpense
276000
CY2024Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
342000
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
316000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
960000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
873000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-853000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-467000
us-gaap Operating Income Loss
OperatingIncomeLoss
-1736000
us-gaap Operating Income Loss
OperatingIncomeLoss
1186000
CY2024Q1 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
0
CY2023Q1 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
0
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
2000
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
13000
CY2024Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
19000
CY2023Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
8000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
70000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
13000
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-834000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-459000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1664000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1212000
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-10000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-6000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-5000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-7000
CY2024Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-824000
CY2023Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-453000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-1659000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
1219000
CY2024Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-572000
CY2023Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-309000
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-4156000
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-1588000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1396000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-762000
us-gaap Net Income Loss
NetIncomeLoss
-5815000
us-gaap Net Income Loss
NetIncomeLoss
-369000
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1396000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-762000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5815000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-369000
CY2024Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.12
CY2023Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.06
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.24
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.17
CY2024Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.12
CY2023Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.06
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.24
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.17
CY2024Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.08
CY2023Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.04
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.59
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.23
CY2024Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.08
CY2023Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.04
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.59
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.23
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.2
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.83
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.2
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.83
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7041
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7032
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7038
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7015
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7041
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7032
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7038
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7018
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
17417000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1344000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
16079000
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-3075000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
13004000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1396000
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
11608000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
19120000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
48000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-1558000
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
17610000
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
1951000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
19561000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-762000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
18799000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2592000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-119000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1089000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
969000
ssy Expenditures For Property Plant And Equipment Discontinued Operations
ExpendituresForPropertyPlantAndEquipmentDiscontinuedOperations
91000
ssy Expenditures For Property Plant And Equipment Discontinued Operations
ExpendituresForPropertyPlantAndEquipmentDiscontinuedOperations
556000
us-gaap Proceeds From Sale Of Other Assets Investing Activities
ProceedsFromSaleOfOtherAssetsInvestingActivities
5000
us-gaap Proceeds From Sale Of Other Assets Investing Activities
ProceedsFromSaleOfOtherAssetsInvestingActivities
213000
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
500000
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-675000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1312000
ssy Proceeds From Share Option Exercises
ProceedsFromShareOptionExercises
6000
ssy Proceeds From Share Option Exercises
ProceedsFromShareOptionExercises
49000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
14000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
30000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-8000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3275000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1412000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4486000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6794000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1211000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5382000
ssy Interest Paid Received Net
InterestPaidReceivedNet
-70000
ssy Interest Paid Received Net
InterestPaidReceivedNet
-46000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
105000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-32000
ssy Right Of Use Asset Obtained In Exchange For Lease Liability
RightOfUseAssetObtainedInExchangeForLeaseLiability
18000
ssy Right Of Use Asset Obtained In Exchange For Lease Liability
RightOfUseAssetObtainedInExchangeForLeaseLiability
24000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 2. – Business Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The Company’s continuing operations are composed of a pharmacy business and an information technology (“IT”) business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The pharmacy business, is composed of four operational areas conducted in three locations in southwest Louisiana:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">· </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Retail pharmacy products and services, consisting of retail pharmacy sales.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">· </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Institutional pharmacy services consisting of the provision of specialty and non-specialty pharmaceutical and biological products to institutional clients or to patients in institutional settings, such as extended care and rehabilitation centers, nursing homes, assisted living facilities, behavioral and specialty hospitals, hospice, and correctional facilities.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">· </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Non-institutional Pharmacy services consisting of the provision of specialty and non-specialty pharmaceutical and biological products to clients or patients in non-institutional settings including private residential homes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">· </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Durable medical equipment products and services (“DME”), consisting primarily of the sale and rental of products for institutional clients or to patients in institutional settings and patient-administered home care.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;"> A </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">subsidiary, SunLink Health Systems Technology (“SHST Technology”), provides information technology (“IT”) services to outside customers and to SunLink subsidiaries. The Company also owns a subsidiary which owns approximately twenty-five (25) acres of unimproved land in Ellijay, Georgia.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Series C Redeemable Preferred Shares</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> On August 2, 2023, the Board of SunLink declared a non-cash dividend per Common Share of one fractional interest in one of the Corporation’s Series C Redeemable Preferred Shares (the “Series C Preferred</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Shares” </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and each such</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fraction </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of a Series C Preferred Share, a “Series C Fractional Interest”). </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each of the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7,032</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Series C Preferred Shares issued was entitled to one million (1,000,000) votes and each Series C Fractional Interest in a Series C Preferred Share was entitled to one thousand (1,000) votes out of such one million votes.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Series C Fractional Interests could not be transferred separately from the Common Shares and were represented by the Common Shares. A further description of the Series C Preferred Shares and the Series C Fractional Interests and the terms and provisions thereof is set forth in the Company’s Current Report on Form 8-K filed with the SEC on August 11, 2023. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each Common Share was entitled to one (1) vote as a Common Share and also one thousand (1,000) votes for the corresponding Series C Fractional Interest thereon, on each matter properly brought before a special shareholders’ meeting which was held on October 19, 2023 and at which the Corporation was reincorporated from the state of Ohio to Georgia (the “Special Meeting”).</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The Series C Fractional Interests were automatically redeemed and the Series C Preferred Shares cancelled.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">COVID-19 Pandemic and CARES Act Funding</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company continued to experience adverse after-effects of the COVID-19 pandemic in the quarter ended March 31, 2024 and believes such effects will likely continue to affect its assets and operations in the foreseeable future, particularly salaries and wages pressure, workforce shortages, supply chain disruption and broad inflationary pressures. Our ability to make estimates of any such continuing effects from current or evolving strains of COVID-19 on future revenues, expenses or changes in accounting judgments that have had or are reasonably likely to have a material effect on our financial statements is limited, depending, as they do, on the severity and length thereof; as well as any further government actions and/or regulatory changes intended to address such effects.</span></p>
CY2023Q4 ssy Transaction Expenses
TransactionExpenses
58000
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
9000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
77452
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7462000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8181000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
24527000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
26270000
CY2024Q1 ssy Reversed Accrued Sales Tax
ReversedAccruedSalesTax
57000
ssy Reversed Accrued Sales Tax
ReversedAccruedSalesTax
437000
ssy Increase In Revenue
IncreaseInRevenue
2615000
CY2023Q2 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
532000
CY2023Q3 us-gaap Financing Receivable Change In Method Credit Loss Expense Reversal
FinancingReceivableChangeInMethodCreditLossExpenseReversal
79000
CY2023Q3 us-gaap Financing Receivable Allowance For Credit Losses Write Offs
FinancingReceivableAllowanceForCreditLossesWriteOffs
203000
CY2023Q3 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
408000
CY2023Q4 us-gaap Financing Receivable Change In Method Credit Loss Expense Reversal
FinancingReceivableChangeInMethodCreditLossExpenseReversal
67000
CY2023Q4 us-gaap Financing Receivable Allowance For Credit Losses Write Offs
FinancingReceivableAllowanceForCreditLossesWriteOffs
104000
CY2023Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
371000
CY2024Q1 us-gaap Financing Receivable Change In Method Credit Loss Expense Reversal
FinancingReceivableChangeInMethodCreditLossExpenseReversal
272000
CY2024Q1 us-gaap Financing Receivable Allowance For Credit Losses Write Offs
FinancingReceivableAllowanceForCreditLossesWriteOffs
363000
CY2024Q1 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
280000
CY2024Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1180000
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1180000
CY2024Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
6000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
19000
CY2024Q1 ssy Finance Lease Obligations
FinanceLeaseObligations
0
CY2023Q2 ssy Finance Lease Obligations
FinanceLeaseObligations
14000
CY2024Q1 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
0
CY2023Q2 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
14000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
605000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
332000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
273000
CY2024Q1 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
0
CY2023Q2 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
0
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-10000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-6000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-5000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-7000
CY2024Q1 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
9499000
CY2024Q1 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2024Q1 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
69000
CY2024Q1 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
29862000
CY2024Q1 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
29862000
CY2024Q1 ssy Net Operating Loss Carry Forwards Expire Period
NetOperatingLossCarryForwardsExpirePeriod
2023 through fiscal year 2038
CY2024Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
85000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
86000
us-gaap Operating Lease Cost
OperatingLeaseCost
255000
us-gaap Operating Lease Cost
OperatingLeaseCost
256000
CY2024Q1 ssy Short Term Lease Cost Income
ShortTermLeaseCostIncome
7000
CY2023Q1 ssy Short Term Lease Cost Income
ShortTermLeaseCostIncome
5000
ssy Short Term Lease Cost Income
ShortTermLeaseCostIncome
19000
ssy Short Term Lease Cost Income
ShortTermLeaseCostIncome
18000
CY2024Q1 ssy Operating Variable Lease Cost
OperatingVariableLeaseCost
0
CY2023Q1 ssy Operating Variable Lease Cost
OperatingVariableLeaseCost
1000
ssy Operating Variable Lease Cost
OperatingVariableLeaseCost
1000
ssy Operating Variable Lease Cost
OperatingVariableLeaseCost
2000
CY2024Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
92000
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
92000
us-gaap Operating Lease Expense
OperatingLeaseExpense
275000
us-gaap Operating Lease Expense
OperatingLeaseExpense
276000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
592000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
798000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
332000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
334000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
273000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
481000
CY2024Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
85000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
86000
us-gaap Operating Lease Payments
OperatingLeasePayments
255000
us-gaap Operating Lease Payments
OperatingLeasePayments
256000
CY2024Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
18000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
16000
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y9M25D
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y8M26D
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y9M25D
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y8M26D
CY2024Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0098
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0102
CY2024Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0098
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0102
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
337000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
252000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
15000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
10000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
0
CY2024Q1 ssy Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
0
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
614000
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
9000
ssy Number Of Taxing Authorities
NumberOfTaxingAuthorities
3
CY2020Q2 us-gaap Income Tax Examination Liability Refund Adjustment From Settlement With Taxing Authority
IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority
359000
ssy Sales Tax Receivable
SalesTaxReceivable
321000
CY2024Q1 ssy Sales Tax Settlement
SalesTaxSettlement
56000
ssy Sales Tax Settlement
SalesTaxSettlement
115000
CY2023Q1 us-gaap Sales And Excise Tax Payable Current And Noncurrent
SalesAndExciseTaxPayableCurrentAndNoncurrent
2615000

Files In Submission

Name View Source Status
0000950170-24-060341-index-headers.html Edgar Link pending
0000950170-24-060341-index.html Edgar Link pending
0000950170-24-060341.txt Edgar Link pending
0000950170-24-060341-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ssy-20240331.htm Edgar Link pending
ssy-20240331.xsd Edgar Link pending
ssy-ex31_1.htm Edgar Link pending
ssy-ex31_2.htm Edgar Link pending
ssy-ex32_1.htm Edgar Link pending
ssy-ex32_2.htm Edgar Link pending
ssy-20240331_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable